<div id="readability-page-1"><div id="parent_top_div"><p>Sun Pharmaceutical Industries on Thursday said it has settled an antitrust litigation in the US entailing a payment of $200 million.</p> <p>  The subsidiaries of the company, Sun Pharmaceutical Industries, Inc. (SPII) and Taro Pharmaceuticals USA, Inc. have signed a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, US, the Mumbai-based drugmaker said in a regulatory filing.</p> <p>  &#34;Under the terms of the settlement agreement, the subsidiaries will make an aggregate payment of $200 million in exchange for a full release of all claims asserted against them in the End Purchaser Action by the settlement class members,&#34; it added.</p> <p>  The settlement amounts may be reduced if more than a certain percentage of the total insured class members opt out of the putative class, the company stated.</p> <p>The settlement agreement is subject to court approval, it added.</p></div></div>

Taro药业

<p>阳光制药工业公司已就一起美国反垄断案件达成 2 亿美元的和解。该公司的子公司 SPII 和 Taro Pharmaceuticals USA 与 “仿制药定价反垄断诉讼案” 中的最终购买者原告达成了协议。和解包括对他们的所有索赔的全面解除，但如果大量投保的集体成员选择退出，支付金额可能会减少。该协议尚待法院批准</p>

太阳制药通过达成 2 亿美元协议解决了美国的反垄断案件